-
公开(公告)号：US20200316143A1
公开(公告)日：2020-10-08
申请号：US16903989
申请日：2020-06-17
IPC分类号： A61K35/742 , A61K31/352 , A61P1/00
摘要： The present invention discloses a method for therapeutic management of atrophic gastritis and colitis using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins. The invention further discloses a method for preventing neoplastic transformation of mucosal cells in gastro-intestinal tract and improving gut barrier function in mammals using a composition comprising Bacillus coagulans MTCC 5856 individually or in combination with anthocyanins.
-
公开(公告)号：US11744807B2
公开(公告)日：2023-09-05
申请号：US17151172
申请日：2021-01-17
IPC分类号： A61K31/122 , A61P11/00 , A61K31/09 , A61K47/10 , A61K36/9066
CPC分类号： A61K31/122 , A61K31/09 , A61K36/9066 , A61K47/10 , A61P11/00
摘要： The present invention discloses a method for therapeutic management of pulmonary fibrosis in mammals using a composition comprising iso-garcinol or octahydrocurcumin or a combination of iso-garcinol and octahydrocurcumin. The composition is very suitable for treating pulmonary fibrosis due to viral infections, specifically COVID 19 and for improving lung function during prognosis.
-
公开(公告)号：US20230201134A1
公开(公告)日：2023-06-29
申请号：US17564490
申请日：2021-12-29
IPC分类号： A61K31/12 , A61K31/585 , A61P25/00
CPC分类号： A61K31/12 , A61K31/585 , A61P25/00
摘要： The invention discloses a composition and method for therapeutically managing a demyelinated disorder through remyelination. The invention includes a composition comprising Withaferin A and Bisdemethoxycurcumin (BDMC), and a pharmaceutically or nutraceutically acceptable excipients, which can be effectively formulated as tablets and capsules. The invention also covers use of composition for effectively managing a demyelinated disorder through remyelination.
-
公开(公告)号：US20230404969A1
公开(公告)日：2023-12-21
申请号：US17944762
申请日：2022-09-14
摘要： The disclosed invention relates to a method comprising composition for effective management of peritonitis in a subject. The invention also discloses a method comprising composition for preventing peritonitis mediated multi organ dysfunction and management of inflammation in a subject. The composition disclosed essentially consists of Witharione.
-
公开(公告)号：US20210220290A1
公开(公告)日：2021-07-22
申请号：US17151121
申请日：2021-01-16
摘要： The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.
-
6.发明授权Composition comprising scirpusin A and scirpusin B and anti-adipogenesis/anti-obesity potential thereof 有权组合物，其包含鞘氨醇蛋白A和柔霉素B及其抗脂肪生成/抗肥胖潜力公开(公告)号：US09387193B2
公开(公告)日：2016-07-12
申请号：US13944634
申请日：2013-07-17
申请人： Muhammed Majeed , Kalyanam Nagabhushanam , Douglas Kalman , Beena Bhat , Priti Vaidyanathan , Sarang Bani , Anjali Pandey
发明人： Muhammed Majeed , Kalyanam Nagabhushanam , Douglas Kalman , Beena Bhat , Priti Vaidyanathan , Sarang Bani , Anjali Pandey
IPC分类号： A61K31/343 , A61K36/8905
CPC分类号： A61K31/343 , A61K36/8905
摘要： Disclosed is a composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof. Also disclosed are methods of inhibiting adipogenesis using a composition comprising scirpusin A and scirpusin B. The present invention also disclosed methods of therapeutically managing obesity in mammals using a composition comprising scirpusin A and scirpusin B. Still further, the present invention also relates to a method of obtaining compositions comprising A. scirpusin A and scirpusin B and B. piceatannol and its dimers scirpusin A and scirpusin B through bioactivity guided fractionation of the rhizomes of Cyperus rotundus.
摘要翻译： 本发明公开了一种组合物，其中含有柔霉素A和柔霉素B及其抗肥胖潜力。 还公开了使用包含灵敏蛋白A和柔红霉素B的组合物来抑制脂肪生成的方法。本发明还公开了使用包含巩螺素A和柔红霉素B的组合物来治疗哺乳动物肥胖的方法。此外，本发明还涉及一种方法 通过生物活性引导分离莎草莎草根茎，获得包含A.Scirpusin A和Scirpusin B和B.piceatannol及其二聚体scirpusin A和scirpusin B的组合物。
-
公开(公告)号：US20200268822A1
公开(公告)日：2020-08-27
申请号：US16386376
申请日：2019-04-17
摘要： The present invention discloses a composition for the therapeutic management of male sexual dysfunction and related disorders. Specifically, the invention discloses a composition comprising 60-65% w/w Withania somnifera extract, 12-18% w/w Mucana pruriens extract, 5-10% w/w Coleus forskolii extract, 12-18% w/w Kaempferia parviflora extract, 0.1-2% w/w Piper nigrum extract, for use as an aphrodisiac.
-
公开(公告)号：US20170128410A1
公开(公告)日：2017-05-11
申请号：US14936830
申请日：2015-11-10
IPC分类号： A61K31/352 , C12N5/077 , G01N33/50
CPC分类号： A61K31/352 , A61K35/35 , C12N5/0653 , C12N2501/01 , C12N2506/13 , G01N33/5044 , G01N2333/51 , G01N2333/515
摘要： Disclosed is a method of achieving optimal mammalian energy balance using forskolin on a particular physiological and developmental stage of the mammalian cellular system.
-
公开(公告)号：US20150306060A1
公开(公告)日：2015-10-29
申请号：US14637081
申请日：2015-03-03
IPC分类号： A61K31/25
CPC分类号： A61K31/25 , A61K31/215
摘要： Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides.
摘要翻译： 公开了哺乳动物高胆固醇血症的治疗管理方法。 更具体地说，本发明涉及一种降低哺乳动物血液中高水平循环胆固醇（高胆固醇血症）的方法，所述方法包括向所述哺乳动物施用治疗有效量的贻贝A以产生（i ）降低总胆固醇含量; （ii）降低低密度脂蛋白（LDL）和极低密度脂蛋白（VLDL）的浓度; （iii）增加高密度脂蛋白（HDL）的浓度和（iv）降低血清甘油三酸酯的浓度。
-
公开(公告)号：US20150306059A1
公开(公告)日：2015-10-29
申请号：US14259404
申请日：2014-04-23
IPC分类号： A61K31/25
CPC分类号： A61K31/25 , A61K31/215
摘要： Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.025 秒)
